Latest News
Shell's ARC Acquisition to Lift Output 13% as Buyback Resumes
Shell's acquisition of ARC Resources cleared with 99.54% shareholder approval, set to boost output by 13.4% while restarting buybacks at 4.1% dilution.
Glencore's Congo Copper Surge Faces Mining Code Overhaul Risk
Glencore's copper output jump was driven by its Congo operations, but a proposed mining code revision poses operational risks.
OpenAI's Speaker Needs 26M Sales to Match $6.5B io Deal Revenue
OpenAI's first consumer hardware, a screenless portable speaker with cameras and sensors, would require 26 million unit sales at $250 each to match the $6.5 billion io deal revenue, facing stiff competition from established smart speakers.
Domino's Expands Board, Appoints Two Independent Directors Ahead of Q2 Earnings
Domino's Pizza (NASDAQ:DPZ) expands board to 10 members and adds two independent directors to its audit committee ahead of Q2 earnings, as the company faces digital execution issues and slowing sales.
PayPal Stock Surges 15% on $53B Bid, Yet Still Trails Offer Price
PayPal surged 14.7% in premarket trading after reports of a $53B-plus bid from Stripe and Advent International, but shares remain 11.4% below the $60.50 offer price.
ASML Lifts 2026 Outlook, Q4 Revenue Seen at €13-16 Billion
ASML raised its 2026 revenue guidance, implying record Q4 sales of €12.9-15.9 billion. Service and upgrade revenue surged 32%, boosting margins.
Xero CEO's Share Sale Triggers A$875 Million Market Cap Wipeout
Xero's CEO sold her remaining shares, triggering a 7% stock decline and A$875 million market value loss. The sale, for tax purposes, intensifies scrutiny on executive pay.
SpaceX Faces $1.24 Trillion Valuation Hurdle Ahead of Starship Test
SpaceX must add $1.24 trillion in value to reach Evercore's $230 target, making Thursday's Starship test a critical checkpoint. Shares closed at $136.08.
India's Crypto Derivatives Surge to 2.4x Holdings as Tax Rules Bite
India's daily crypto turnover reaches $5 billion, with futures trading accounting for 80% of volume as traders seek to avoid heavy spot taxes. Retail investors dominate but face high risks.
Attovia Therapeutics Files IPO to Challenge Dupixent and Nemluvio
Attovia Therapeutics has filed for an IPO to raise capital for developing rival treatments to Sanofi and Regeneron's Dupixent and Galderma's Nemluvio.
